SCI says Elekta's Monaco 3.20 is superior to existing VMAT planning systems
In retrospective plan comparisons of ten previously treated patients with cancer and two clinical SBRT cases, physicists at Swedish Cancer Institute (SCI) in Seattle, WA have discovered that Elekta's latest release of Monaco treatment planning system - version 3.20 - provides significant benefits in dose conformity, delivery efficiency and sparing of organs-at-risk. SCI has been evaluating Monaco 3.20 since April.
In VMAT planning cases, physicists led by SCI Medical Physicist Dr Daliang Cao, compared Monaco 3.20 with the previous version of Monaco and found that Monaco 3.20 with Segment Shape Optimization (SSO) can provide much more uniform target dose without significantly compromising the sparing of critical normal structures. Compared with the previous version, they also observed that Monaco 3.20 reduced beam delivery time by 37 per cent (1.3 minutes) in some cases.